Terlipressin Administration in Septic Shock Refractory to Catecholamines

Shamir Medical Center (Assaf-Harofeh)

Status and phase: Unknown; Phase 2

Conditions: Septic Shock

Treatments: Drug: terlipressin

Study type: Interventional

Funder types: Other

Identifiers

NCT00793559

161/08

Details and patient eligibility

About

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• septic shock patients receiving above 0.5 mcg/kg NA

Exclusion criteria

• allergy to terlipressin, CHF, IHD, pregnancy

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

terlipressin bolus

Active Comparator group

Description:

1 mg of terlipressin received one time only

Treatment:

Drug: terlipressin

Drug: terlipressin

terlipressin drip

Experimental group

Treatment:

Drug: terlipressin

Drug: terlipressin